Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yang Cheng

Showing results (1031-1040 of 1,102) with videos related to

Pageof 111
Sort By:
The Journal of Biological Chemistry|November 11, 2017
The nonproton ligand of acid-sensing ion channel 3 activates mollusk-specific FaNaC channels via a mechanism independent of the native FMRFamide peptideXiao-Na Yang, You-Ya Niu, Yan Liu, et al.
Expert Opinion on Investigational Drugs|February 9, 2023
Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjectsYanli Wang, Jinling Xue, Zhengjie Su, et al.
Expert Opinion on Drug Metabolism & Toxicology|August 12, 2022
A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjectsZhengzhi Liu, Zhenyue Gao, Wei Yang, et al.
Mutation Research|February 13, 2016
Genetic variants in multisynthetase complex genes are associated with DNA damage levels in Chinese populationsJia Liu, Meng Zhu, Weihong Chen, et al.
Malaria Journal|May 24, 2017
Naturally acquired humoral and cellular immune responses to Plasmodium vivax merozoite surface protein 8 in patients with P. vivax infectionYang Cheng, Bo Wang, Siriruk Changrob, et al.
Journal for Immunotherapy of Cancer|February 3, 2024
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumorsSandip P Patel, Teresa Alonso-Gordoa, Susana Banerjee, et al.
Gastroenterology|February 3, 2005
Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infectionSébastien Dharancy, Mathilde Malapel, Gabriel Perlemuter, et al.
Cryobiology|March 19, 2023
Effects of sericin on oxidative stress and PI3K/AKT/mTOR signal pathway in cryopreserved mice ovarian tissueWei Han Shu, Song He Yang, Meng Wei, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|February 20, 2025
VRK2 promotes colorectal cancer growth and impedes immunotherapy and 5-FU treatment efficacyYu-Tong Wu, Meng Gao, Kun-Yang Cheng, et al.
International Immunopharmacology|April 23, 2022
A randomized, crossover, phase I clinical study to evaluate bioequivalence and safety of tofacitinib and Xeljanz® in Chinese healthy subjectsZhongnan Xu, Yanli Wang, Zhengzhi Liu, et al.
Pageof 111

Showing results (1031-1040 of 1,102) with videos related to

Sort By:
Pageof 111
The Journal of Biological Chemistry|November 11, 2017
The nonproton ligand of acid-sensing ion channel 3 activates mollusk-specific FaNaC channels via a mechanism independent of the native FMRFamide peptideXiao-Na Yang, You-Ya Niu, Yan Liu, et al.
Expert Opinion on Investigational Drugs|February 9, 2023
Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjectsYanli Wang, Jinling Xue, Zhengjie Su, et al.
Expert Opinion on Drug Metabolism & Toxicology|August 12, 2022
A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjectsZhengzhi Liu, Zhenyue Gao, Wei Yang, et al.
Mutation Research|February 13, 2016
Genetic variants in multisynthetase complex genes are associated with DNA damage levels in Chinese populationsJia Liu, Meng Zhu, Weihong Chen, et al.
Malaria Journal|May 24, 2017
Naturally acquired humoral and cellular immune responses to Plasmodium vivax merozoite surface protein 8 in patients with P. vivax infectionYang Cheng, Bo Wang, Siriruk Changrob, et al.
Journal for Immunotherapy of Cancer|February 3, 2024
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumorsSandip P Patel, Teresa Alonso-Gordoa, Susana Banerjee, et al.
Gastroenterology|February 3, 2005
Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infectionSébastien Dharancy, Mathilde Malapel, Gabriel Perlemuter, et al.
Cryobiology|March 19, 2023
Effects of sericin on oxidative stress and PI3K/AKT/mTOR signal pathway in cryopreserved mice ovarian tissueWei Han Shu, Song He Yang, Meng Wei, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|February 20, 2025
VRK2 promotes colorectal cancer growth and impedes immunotherapy and 5-FU treatment efficacyYu-Tong Wu, Meng Gao, Kun-Yang Cheng, et al.
International Immunopharmacology|April 23, 2022
A randomized, crossover, phase I clinical study to evaluate bioequivalence and safety of tofacitinib and Xeljanz® in Chinese healthy subjectsZhongnan Xu, Yanli Wang, Zhengzhi Liu, et al.
Pageof 111